Response to 5-fluorouracil of orthotopically xenografted human colon cancers with a microsatellite instability: Influence of p53 status

Anticancer Research

Volumn 20, Issue 1 A, 2000, Pages 85-90

  Pocard, Marc ^a   Bras Gonçalves, Rui ^b   Hamelin, Richard ^b   Northover, John ^a   Poupon, Marie France ^b  

^a ST MARK S HOSPITAL   (United Kingdom)

^b INSTITUT CURIE   (France)

Author keywords

5 fluorouracil; Human colorectal cancer; Microsatellite instability; Nude mice; Orthotopic model; P53 gene

Indexed keywords

FLUOROURACIL; MUTANT PROTEIN; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; COLON CANCER; CONTROLLED STUDY; FEMALE; GENETIC TRANSFECTION; MICROSATELLITE INSTABILITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; XENOGRAFT;

ADENOCARCINOMA; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CECUM; COLONIC NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; GENES, DOMINANT; GENES, P53; HUMANS; MICE; MICE, NUDE; MICROSATELLITE REPEATS; MUTATION; NEOPLASM TRANSPLANTATION; PHENOTYPE; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0343183947     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Fearon E and Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 61: 759-767, 1990.
2. Fearon ER: Colorectal cancer: molecular genetic studies and their future clinical applications. Med Pediatric Oncol - Supplement 1; 35-40, 1996.
3. Kinsella AR, Smith D and Pickard M: Resistance to chemotherapeutic antimetaholites: a function of salvage pathway involvement and cellular response to DNA damage. Br J Cancer 75: 933-945, 1997.
4. Rougier P, Paillot B, LaPlanche A, Morvan F, Seitz JF, Rekacewicz C, Laplaige P, Jacob J, Grandjouan S, Tigaud JM, Fabri MC, Luboinski M and Ducreux M: 5-Fluorouracil (5-FU) continuous intravenous infusion compared with bolus administration. Final results of a randomised trial in metastatic colorectal cancer. Eur J Cancer. 33: 1789-1793, 1997.
5. Etienne MC, Guillot T and Milano G Critical factors for optimizing the 5-fluorouracil- folinic acid association in cancer chemotherapy. Ann Oncol 7: 283-289, 1996.
6. Lothe RA, Peltomaki P, Meling GI, Aaltonen LA, Nystrom-Lahti M, Pylkkanen L, Heimbal K, Andersen TI, Moller P, Rognum TO, Fossa SD, Haldorsen T, Langmark F, Brogger A, Chapelle ADI and Borresen AL: Genomic instability in colorectal cancer relationship to clinicopathological variables and family history. Cancer Res 53: 5849-5852, 1993.
7. Lengauer C, Kinzler KW and Vogelstein B: Genetic instability in colorectal cancers. Nature 386: 623-627, 1997.
8. Olschwang S, Hamelin R, Laurent-Puig P, Thuille B, De Rycke Y, Li YJ, Muzeall F, Girodet J, Salmon RJ and Thomas G: Alternative genetic pathways in colorectal carcinogenesis. Proc Natl Acad Sci USA 94: 12122-12127, 1997.
9. Hamelin R, Laurent-Puig P, Olschwang S, Jego N, Asselain B, Remvikos Y, Girodet J, Salmon RJ and Thomas G: Association of p53 mutations with short survival in colorectal cancer. Gastroenterology 100: 42-48, 10, 1994.
10. Ilyas M, Tomlinson IP, Novelli MR, Hanby A, Bodmer WF and Talbot IC: Clinico-pathological features and p53 expression in leftsided sporadic colorectal cancers with and without microsatellite instability. J Pathol 779: 370-375, 1996.
11. Benhattar J, Cerottini JP, Saraga E, Metthez G and Givel JC: p53 mutations as a possible predictor of response to chemotherapy in metastatic colorectal carcinomas. Int J Cancer 69: 190-192, 1996.
12. Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB and Roth JA: Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wildtype p53 gene. Cancer Res 54: 2287-2291, 1994.
13. Lowe SW, Ruley HE, Jacks T and Housman DE: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957-967, 1993.
14. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE and Jacks T: p53 status and the efficacy of cancer therapy in vivo. Science 266: 807-810, 1994.
15. Brett MC, Pickard M, Green B, Howel-Evans A, Smith D, Kinsella A and Poston G: p53 protein overexpression and response to biomodulated 5-fluorouracil chemotherapy in patients with advanced colorectal cancer. Eur J Surg Oncol 22: 182-185, 1996.
16. Paradiso A, Rabinovich M, Vallejo C, Machiavelli M, Romero A, Perez J, Lacava J, Cuevas MA, Rodriquez R, Leone B, Sapia MG, Simone G and De Lena M: p53 and PCNA expression in advanced colorectal cancer: response to chemotherapy and long- term prognosis. Int J Cancer 69: 437-441, 1996.
17. Casares S, Ionov Y, Ge HY, Stanbridge E and Perucho M: The microsatellite mutator phenotype of colon cancer cells is often recessive. Oncogene 11: 2303-2310, 1995.
18. Hamelin R, Jego N, Laurent-Puig P, Vidaud M and Thomas G: Efficient screening of p53 mutations by denaturing gradient gel electrophoresis in colorectal tumors. Oncogene 8: 2213-2220, 1993.
19. Pocard M, Chevillard S, Villaudy J, Poupon MF, Dutrillaux B and Remvikos Y: Different p53 mutations produce distinct effects on the ability of colon carcinoma cells to become blocked at the G1/S boundary after irradiation. Oncogene 12: 875-882, 1996.
20. Cottu, PH, Muzeau F, Estreicher A, Flejou JF, Iggo R, Thomas G and Hamelin R: Inverse correlation between RER+ status and p53 mutation in colorectal cancer cell lines. Oncogene 13: 2727-2730, 1996.
21. Pocard M, Muleris M, Hamelin R, Salmon R-J, Dutrillaux B and Poupon M-F: Growth dependency of human colon cancer xenograft on organ environment is related with their original clinical stage. Anticancer Res 18: 2743-2748, 1998.
22. Remvikos Y, Muleris M, Salmon RJ and Dutrillaux, B: Colorectal carcinogenesis: from chromosomal evolution pathways to molecular pathogenesis. Cancer Genet Cytogenet 93: 63-73, 1997.
23. Bubb VJ, Curtis LJ, Cunningham C, Dunlop MG, Carothers AD, Morris RG, White S, Bird CC and Wyllie AH: Microsatellite instability and the role of hMSH2 in sporadic colorectalcancer. Oncogene 12: 2641-2649, 1996.
24. Dos Santos NR, Seruca R, Constancia M, Seixas M and Sobrinho-Simoes M: Microsatellite instability at multiple loci in gastric carcinoma: clinicopathologic implications and prognosis. Gastroenterology 110: 38-44, 1996.
25. Lukish JR, Muro K, DeNobile J, Katz R, Williams J, Cruess DF, Drucker W, Kirsch I and Hamilton SR: Prognostic significance of DNA replication errors in young patients with colorcctal cancer. Ann Surg 227: 51-56, 1998.
26. Vaurs C and Bignon YJ: What's new about microsatellite instability significance in human carcinogenesis? Bull Cancer 84: 1061-1071, 1997.
27. Arnheim N and Shibata D: DNA mismatch repair in mammals: role in disease and meiosis. Curr Opin Gen Dev 7: 364-370, 1997.
28. Ishimaru G, Adachi J, Shiseki M, Yamaguchi N, Muto T and Yokota J: Microsatellite instability in primary and metastatic colorectal cancers. Int J Cancer 64: 153-157, 1945.
29. Ceraline J, Deplanque G, Duclos B, Limacher JM, Hajri A, Noel F, Orvain C, Frebourg T, Klein-Soyer C and Bergerat JP: Inactivation of p53 in normal human cells increases G2/M arrest and sensitivity to DNA-damaging agents. Int J Cancer 75: 432-438, 1998.
30. Fan S, el-Deiry WS, Bae I, Freeman J, Jondle D, Bhatia K, Fornace AJ, Magrath I, Kohn KW and O'Connor PM: p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res 54: 5824-5830, 1994.
31. McDonald AC and Brown R: Induction of p53-dependent and p53-independent cellular responses by topoisomerase 1 inhibitors. Br J Cancer 78: 745-751, 1998.
32. An Z, Wang X, Astoul P, Danays T, Moossa AR and Hoffman RM: Interferon gamma is highly effective against orthotopicalty-implanted human pleural adenocarcinoma in nude mice. Anticancer Res 16: 2545-2551, 1996.
33. An Z, Wang X, Willmott N, Chander SK, Tickle S, Docherty AJ, Mountain A, Millican AT, Morphy R, Porter JR. Epemolu RO, Kubota T, Moossa AR and Hoffman RM: Conversion of highly malignant colon cancer from an aggressive to a controlled disease by oral administration of a metalloproteinase inhibitor. Clin Exp Met 15: 184-195, 1997.
34. Dong Z, Radinsky R, Fan D, Tsan R, Bucana CD, Wilmanns C and Fidler IJ: Organ-specific modulation of steady-state mdr gene expression and drug resistance in murine colon cancer cells. J Natl Cancer Inst 86: 913-920, 1994.
35. Fidler IJ: Modulation of the organ microenvironment for treatment of cancer metastasis. J Natl Cancer Inst 87: 1588-1592, 1995.
36. Fidler IJ, Wilmanns C, Staroselsky A, Radinsky R, Dong Z and Fan D: Modulation of tumor cell response to chemotherapy by the organ environment. Cancer Met Rev 13: 209-222, 1994.
37. Kuo TH, Kubota T, Watanabe M, Furukawa T, Teramoto T, Ishibiki K, Kitajima M, Moossa AR, Penman S and Hoffman RM: Liver colonization competence governs colon cancer metastasis. Proc Natl Acad Sci USA 92: 12085-12089, 1995.
38. Wilmanns C, Fan D, O'Brian CA, Radinsky R, Bucana CD, Tsan R and Fidler IJ: Modulation of doxorubicin sensitivity and level of P-glycoprotein expression in human colon carcinoma cells by ectopic and orthotopic environments in nude mice. Int J Oncol 3: 413-422, 1993.
39. Inada T, Ichikawa A, Kubota T, Ogata Y, Moossa AR and Hoffman RM: 5-FU-induced apoptosis correlates with efficacy against human gastric and colon cancer xenografts in nude mice. Anticancer Res 17: 1965-1971, 1997.
40. Pickard M, Dive C and Kinsella AR: Differences in resistance to 5-fluorouracil as a function of cell cycle delay and not apoptosis. Br J Cancer 72: 1389-1396, 1995.
41. Pickard M and Kinsella AR: Influence of both salvage and DNA damage response pathways on resistance to chemotherapeutic antimetabolites. Biochem Pharmacol 52: 425-431, 1996.
42. Johnston PG, Fisher ER, Rockette HE, Fisher B, Wolmark N, Drake JC, Chabner BA and Allegra CJ: The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 12: 2640-2647, 1994.
43. Lenz HJ, Danenherg KD, Leichman CG, Florentine B, Johnston PG, Groshen S, Zhou L, Xiong YP, Danenberg PV and Leichman LP: p53 and thymidylate synthase expression in untreated stage 11 colon cancer: associations with recurrence, survival, and site. Clin Cancer Res 4: 1227-1234, 1998.
44. Lenz HJ, Hayashi K, Salonga D, Danenberg KD, Danenberg PV, Metzger R, Banerjee D, Bertino JR, Groshen S, Leichman LP and Leichman CG: p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival. Clin Cancer Res 4: 1243-1250, 1998.